ATAI Life Sciences AG

Congratulations to Cosmo Feilding Mellen, Rob Conley and the team at Beckley Psytech on the encouraging Phase 2a results for ELE-101. While this is an early proof-of-concept study, the safety and efficacy signals are promising. We're proud to support Beckley Psytech as we continue our mission to develop scalable interventional psychiatry treatments for depression.

Our SVP of Clinical Development, Kevin Craig, recently shared the purpose behind his work with Alexandria Wise from Syneos Health.   "The brain is probably the most difficult set of problems to face," Kevin reflected, describing his journey from research to medicine and back. His experiences as a physician shaped his commitment to finding tangible solutions for those in need.   Kevin’s focus on bridging research and real-world impact stands out: "I think much more about how treatments get into patients’ lives, make a difference, and become accessible."   This mission to make mental health treatments accessible to everyone, everywhere is central to atai—and Kevin’s work is helping make it a reality. Listen to the full podcast below. ⬇️

Transforming mental health care means thinking beyond the lab – we must take a pragmatic approach for real-world application. This is the core message our co-CEO Srinivas Rao discussed with Brandon Li on the latest Power to the Patient podcast. At atai, we’re not just developing new therapies; we’re ensuring they can make a meaningful difference for patients and providers. New mental health treatments will only reach large-scale impact if they can be easily adopted by health systems and accessible to patients. That’s why a pragmatic, commercially-minded approach is core to what we do, as we explore the potential of psychedelic-based compounds to treat mental health disorders. In this episode, Srini and Brandon dive into: ▶️ Our focus on hard-to-treat conditions like treatment-resistant depression (TRD) and social anxiety disorder (SAD) ▶️ How we design treatments with the commercial end in mind – including innovative approaches to formulations, novel routes of administration and short treatment windows ▶️ The importance of balancing innovation with real-world applicability We’re proud to be at the forefront of this important work. Tune in to the full conversation below to hear how we’re keeping patients and providers at the heart of everything we do. Full episode here: https://lnkd.in/gaXJGSbp

Last week, our team attended the 2024 CNS Summit in Boston, joining some of the brightest minds in life sciences to discuss the future of psychedelic medicine. Some key highlights: • Psychedelic Forum: Our Co-CEO, Srinivas Rao, participated in a panel with industry leaders to discuss the path forward for psychedelic medicine. The key takeaway: rigorous data and regulatory approval are essential to delivering new treatments to those in need. • Rethinking Patient Trust: Our SVP of Clinical Development, Kevin Craig, joined experts to discuss how to build trust in psychiatric trials, focusing on transparency, care, and valuing participants—the foundation of progress in this field. The summit was a powerful reminder of how science, collaboration, and innovation can drive real change in mental health care. Together with our peers, we’re committed to developing transformative treatment options.

Today we shared our Q3 financial results and corporate updates as we move towards the end of 2024 with strong momentum across our pipeline. Our Co-CEO and Co-Founder Dr. Srinivas Rao said, “We are on track to initiate Phase 2 trials for VLS-01 and EMP-01 around year-end and we look forward to topline Phase 2b data from Beckley Psytech’s BPL-003 in the second quarter of 2025. Our team is focused on executing these trials with the utmost scientific rigor and is driven by our goal of being the leader in developing new psychedelic treatment options to mental health patients in need of innovative, safe and effective solutions.” With a dedicated team and a strong pipeline, we’re making steady progress toward delivering new, effective solutions in mental health. Read more: https://buff.ly/3UKSBqI #MentalHealth #Biotech #Q3 #Earnings

Numbness. Hollowness. Hopelessness. These are just some of the words used to describe what it’s like living with depression. Every day, over 300 million people worldwide face this struggle. For one-third of them, relief remains out of reach. These individuals live with treatment-resistant depression (TRD), a form of depression that is unresponsive to current treatment options. Many live with the fear of never feeling better.They might not see a path forward, but they deserve one. That’s why we’re proud to share the next video in our One Billion People series, shedding light on what it’s like to live with TRD. We’re committed to bringing new hope and possibility to those who have none, by advancing innovative mental health treatment options grounded in rigorous science. If you or someone you know is struggling with thoughts of self-harm or suicide, please know that help is available. Reach out to a friend, a family member, or call a suicide prevention hotline. #OneBillionPeople #MentalHealth

Next week our team is heading to Boston for the #CNSSummit2024. Our co-founder and co-CEO, Srinivas Rao and Senior Vice President of Clinical Development Kevin Craig will share their insights on the remarkable advancements in science over the past 15 years. They'll explore the transformative potential of psychedelics in mental health treatment and discuss how atai prioritizes patient needs in our clinical trial designs. We can’t wait to learn from industry leaders, connect with peers and forge new relationships. If you’re attending, let us know—we’d love to connect!

Last week, our Senior Director of Neurobiology, Carrie Bowen, presented a poster at the 2024 Society for Neuroscience (SfN) meeting on atai's recent discoveries of novel, selective 5-HT2A receptor agonists with non-hallucinogenic potential for treatment-resistant depression (TRD).    Up to 300 million people globally live with depression; a third of whom find no relief from current treatment options because they suffer from TRD. To address this huge unmet need, Carrie and the rest of the Discovery team are focused on identifying novel molecules using artificial intelligence and machine learning informed drug design and medicinal chemistry to discover a treatment that could, one day, have the potential to offer durable efficacy and flexible dosing options for people living with TRD.   Thanks Carrie for reminding us how cool science is!    Learn more about this program and our discovery efforts by reading Carrie's poster ⬇️  https://lnkd.in/gTi38MbK 

To mark this year’s Mental Health Awareness Day we are proud to launch the first video in our new series, One Billion People. In the spirit of prioritizing our mental health, the atai team is taking a company-wide day off. That’s why we are proud to share the video with you today. More than one billion people worldwide suffer from mental health disorders. Many of whom have limited or no effective treatment options, and little hope for a better future. Our new video series shines a light on these individuals, starting with those living with social anxiety disorder, also known as SAD. SAD causes intense fear, self-consciousness and embarrassment in social interactions. The number of people suffering with SAD has dramatically risen over the last few years, affecting 18 million adults in the U.S alone. Despite the growing number of people impacted, there have been no new treatments for more than 20 years. Learn what it’s like to live with SAD, and why those living with it deserve new and effective treatment options. 🎥 #OneBillionPeople #WorldMentalHealthDay To learn more about our programs, visit: https://buff.ly/3U3HEjE

Our Co-Founder, Co-CEO, and Chief Scientific Officer Srinivas Rao will share his insights on the Advancement in Psychedelic Therapies for Neuropsychiatry panel during the 4th Annual Novel Mechanisms in Neuropsychiatry Summit. You can watch the virtual conversation live tomorrow at 10am EST using the link ⬇️ #TDCowenHealthCare #MentalHealth https://lnkd.in/gdfPZXmN